Drugs Made In America Acquisition II Corp.

Drugs Made In America Acquisition II Corp. (Nasdaq: DMIIU) is a blank-check company formed to pursue a business combination in the pharmaceutical and domestic drug manufacturing sector. The SPAC is the second vehicle from the Drugs Made In America sponsor franchise, which focuses on reshoring and scaling U.S.-based drug production. The company filed an 8-K with the SEC on March 6, 2026, under accession number 0001213900-26-024763, reflecting a material corporate development during its search phase. DMIIU targets acquisition opportunities in healthcare and pharmaceutical manufacturing, consistent with the broader domestic-supply-chain theme that defines the sponsor's investment thesis. Visit SpacDesk and sign up for full data, filings, and deal-tracking on DMIIU and hundreds of other active SPACs.